Beta-Defensins: Epithelial Barrier Peptides
Defensins
40+ human beta-defensin genes
The DEFB gene cluster on chromosome 8 encodes over 40 beta-defensin genes, making them the most diverse antimicrobial peptide family in the human genome.
Zhao et al., Biochemical Pharmacology, 2024
Zhao et al., Biochemical Pharmacology, 2024
View as imageEvery surface of your body that contacts the outside world produces beta-defensins. Skin, airways, intestinal lining, urogenital tract: wherever epithelial cells form a barrier, these small cationic peptides stand guard. Unlike alpha-defensins, which are stored in neutrophil granules and deployed during acute immune responses, beta-defensins are produced directly by the barrier cells themselves.[1] This makes them the first antimicrobial molecules a pathogen encounters when it contacts an epithelial surface.
What distinguishes beta-defensins from simple antimicrobial agents is their range of functions. They kill bacteria, fungi, and enveloped viruses through membrane disruption. They recruit dendritic cells and memory T cells to sites of barrier breach. They regulate the composition of the microbiome. And they maintain epithelial tight junction integrity, the physical seals between cells that prevent pathogens from crossing the barrier.[2]
Key Takeaways
- The human genome encodes over 40 beta-defensin genes in the DEFB cluster on chromosome 8, making them the most diverse antimicrobial peptide family (Zhao et al., 2024)
- hBD-1 is constitutively expressed at epithelial surfaces and provides continuous baseline defense against Gram-negative bacteria and Candida (Singh et al., 1998)
- hBD-2 is inducible by infection and inflammation, upregulates tight junction proteins occludin and ZO-1, and shifts macrophage polarization toward the reparative M2 phenotype (Da Silva et al., 2025)
- hBD-3 has the broadest antimicrobial spectrum among beta-defensins, killing both Gram-positive and Gram-negative bacteria including MRSA (Scudiero et al., 2020)
- Keratinocyte-derived defensins activate neutrophil-specific Mrgpr receptors to prevent skin dysbiosis, a mechanism published in Immunity (Dong et al., 2022)
- Beta-defensins shape microbiome composition by selectively killing pathogenic bacteria while sparing commensals (Meade et al., 2018)
The Beta-Defensin Family
Beta-defensins are small cationic peptides, typically 35 to 45 amino acids long, characterized by six conserved cysteine residues that form three disulfide bonds in a specific pattern (Cys1-Cys5, Cys2-Cys4, Cys3-Cys6). This disulfide arrangement differs from alpha-defensins and creates a distinctive beta-sheet structure that is remarkably stable across a wide range of pH and temperature conditions.[1]
Four human beta-defensins have been the most extensively studied:
hBD-1 is constitutively expressed by epithelial cells throughout the body. It provides continuous, baseline antimicrobial defense without requiring an infection trigger. In 1998, Singh et al. demonstrated that human airway epithelial cells produce beta-defensins, establishing for the first time that the airway surface liquid contains endogenous antibiotics.[3] hBD-1 is primarily active against Gram-negative bacteria and Candida species. Its constitutive expression means it functions as the always-on sentry of epithelial defense.
hBD-2 is the inducible member of the family. Its expression is upregulated by bacterial infection, inflammatory cytokines (IL-1beta, TNF-alpha), and activation of Toll-like receptors. This makes hBD-2 the alarm-response defensin: production ramps up when the barrier is under threat. Wozniak et al. (2024) identified specific human host factors required for hBD-2 expression in intestinal epithelial cells, including NOD2-dependent signaling pathways.[4] Kim et al. (2018) demonstrated that hBD-2 also plays a regulatory role in innate antiviral immunity, capable of potentiating antigen-specific immune responses.[5]
hBD-3 has the broadest antimicrobial spectrum among the beta-defensins. Scudiero et al. (2020) showed that human defensins, particularly hBD-3, represent a novel approach against skin-colonizing Staphylococcus aureus, including methicillin-resistant strains.[6] Unlike hBD-1 and hBD-2, which primarily target Gram-negative bacteria, hBD-3 kills Gram-positive organisms with equal efficiency. It is also chemotactic for dendritic cells and memory T cells through the CCR6 receptor.
hBD-4 has the most restricted expression pattern, found primarily in the testes and stomach, with inducible expression in some other epithelial tissues. It can recruit monocytes but, unlike the other beta-defensins, does not appear to induce CCR6-mediated chemotaxis.
Beta-Defensins in Skin Defense
The skin is the largest epithelial barrier organ, and beta-defensins form a critical component of its antimicrobial defense. Keratinocytes express hBD-1 constitutively and upregulate hBD-2 and hBD-3 in response to infection, injury, or inflammatory stimuli.
Dong et al. (2022) published a study in Immunity demonstrating a previously unknown mechanism: keratinocyte-derived defensins activate neutrophil-specific Mrgpra2a/b receptors, preventing skin dysbiosis.[7] This finding revealed that defensins do not only kill pathogens directly; they also communicate with neutrophils to coordinate a broader antimicrobial response that maintains skin microbial balance.
Strajtenberger et al. (2024) explored the connection between hBD-2 and skin disease, finding that this defensin links infections to allergic skin conditions.[8] When hBD-2 levels are altered, either through genetic variation or chronic inflammatory conditions, the skin becomes more susceptible to both infection and allergic pathology. This dual role in antimicrobial defense and immune regulation is characteristic of the entire beta-defensin family.
Kaya et al. (2026) investigated serum hBD-2 levels in psoriasis and psoriatic arthritis patients, providing evidence that beta-defensin dysregulation contributes to chronic inflammatory skin disease.[9] These findings suggest that beta-defensins are not simply antimicrobial tools but active participants in skin immune homeostasis. For more on how peptides approach wound healing in the skin, see antimicrobial peptides in wound care.
Beta-Defensins in the Gut
The intestinal epithelium faces a unique challenge: it must tolerate trillions of commensal bacteria while defending against pathogens. Beta-defensins are central to this selective defense.
Meade et al. (2018) published a comprehensive review titled "Farming the Microbiome for Homeostasis and Health," documenting how beta-defensins shape the composition of the gut microbiome rather than simply sterilizing the intestinal environment.[10] Different defensins have different antimicrobial spectra, which means the specific combination of defensins expressed in a given region of the gut selectively pressures certain bacterial populations while allowing others to thrive. This creates a defensin-mediated filter that helps maintain a healthy microbiome composition.
Wozniak et al. (2024) identified human host factors required for hBD-2 expression in intestinal epithelial cells, establishing that NOD2 (nucleotide-binding oligomerization domain-containing protein 2) signaling is essential for intestinal hBD-2 production.[4] This is clinically relevant because NOD2 mutations are strongly associated with Crohn's disease, and impaired defensin production may be one mechanism through which these mutations lead to intestinal inflammation. When the gut cannot produce adequate defensins, pathogenic bacteria gain a foothold and trigger chronic inflammation.
Shimizu et al. (2022) found that elderly people have lower levels of human defensin 5 compared to middle-aged adults, and that this reduction is associated with differences in the gut microbiota.[11] The age-related decline in defensin production may contribute to the increased susceptibility to intestinal infections and the altered microbiome composition observed in older populations. For more on how defensins maintain intestinal microbial balance, see defensins and the gut.
Beta-Defensins in the Airways
The respiratory tract is continuously exposed to inhaled pathogens, and beta-defensins provide the first line of chemical defense on the airway surface.
Singh et al. (1998) made the landmark discovery that human airway epithelial cells produce beta-defensins, demonstrating that the thin layer of liquid covering the airway surface contains endogenous antimicrobial peptides.[3] This finding, published in the Proceedings of the National Academy of Sciences, fundamentally changed the understanding of lung defense by showing that airways do not rely solely on mucus clearance and recruited immune cells; they manufacture their own chemical weapons.
hBD-1 is constitutively expressed in airway epithelial cells, providing continuous baseline defense. hBD-2 is induced by bacterial infection through TLR-dependent pathways. hBD-3 is also inducible and provides the broadest-spectrum activity, which is particularly relevant in airways where both Gram-positive and Gram-negative pathogens must be addressed.
The clinical relevance of airway beta-defensins is demonstrated most clearly in cystic fibrosis. In cystic fibrosis, the abnormal salt concentration and dehydrated airway surface liquid inactivate defensins, reducing their antimicrobial effectiveness. This contributes directly to the chronic bacterial infections, particularly by Pseudomonas aeruginosa and Staphylococcus aureus, that define the disease and drive progressive lung damage. For more on how defensins protect the respiratory tract, see defensins against influenza and COVID. Beta-defensins work alongside LL-37, the cathelicidin antimicrobial peptide whose production is regulated by vitamin D.
Beyond Killing: Immune Signaling and Barrier Integrity
The functions of beta-defensins extend well beyond direct antimicrobial activity. Three additional roles are now well-documented.
Chemotaxis and immune cell recruitment. Beta-defensins are chemotactic for CCR6-expressing cells, including immature dendritic cells and memory T cells. This means that when beta-defensins are produced at a site of barrier breach, they not only kill pathogens directly but also recruit the adaptive immune system to mount a targeted response. This bridges the gap between innate and adaptive immunity in a way that few other molecules can. The chemotactic activity operates at nanomolar concentrations, far below the micromolar levels required for direct antimicrobial killing, which means defensins begin recruiting immune cells before they accumulate to bactericidal levels. This early warning function gives the adaptive immune system a head start in responding to barrier breaches. For how this selectivity mechanism works, see how defensins distinguish bacteria from your own cells.
Tight junction maintenance. hBD-2 has been shown to protect epithelial barrier integrity by upregulating the expression of tight junction proteins occludin and ZO-1. During bacterial infection, tight junctions are often disrupted, allowing pathogens and their products to cross the epithelial barrier. By reinforcing these junctions, hBD-2 acts as both an antimicrobial agent and a structural barrier protector.
Wound healing. Da Silva et al. (2025) showed that hBD-2 loaded in alginate hydrogels accelerated wound closure in diabetic mice, reduced the M1/M2 macrophage ratio, lowered reactive oxygen species, and increased collagen deposition.[12] Migliario et al. (2023) demonstrated that laser biostimulation induces beta-defensin 2 expression in human keratinocytes, linking photobiomodulation therapy to defensin-mediated wound healing.[13]
Current Limitations and Open Questions
Expression regulation complexity. Beta-defensin production is controlled by a network of signaling pathways (NF-kB, MAPK, NOD2, TLR) that interact in complex ways. Understanding how to therapeutically upregulate specific defensins without triggering excessive inflammation remains a challenge.
Copy number variation. The DEFB gene cluster on chromosome 8 shows significant copy number variation between individuals, meaning people carry anywhere from two to twelve copies of certain beta-defensin genes. Higher copy numbers are associated with increased defensin expression. Lower copy numbers correlate with susceptibility to Crohn's disease, psoriasis, and certain infections. This genetic variation creates a spectrum of baseline antimicrobial capacity across the population, but the full functional implications of specific copy number states are not yet mapped.
Therapeutic delivery. Like other antimicrobial peptides, beta-defensins face stability challenges when used as topical therapeutics. Protease degradation in the wound or mucosal environment limits their half-life. The hydrogel delivery approach used by Da Silva et al. (2025) for hBD-2 shows one path forward.[12]
Microbiome effects. While beta-defensins shape the microbiome, the full consequences of therapeutic defensin administration on beneficial microbial populations are not established. For more on this balance, see antimicrobial peptides and microbiome balance.
The Bottom Line
Beta-defensins are the epithelial immune system's primary chemical defense, produced at every barrier surface from skin to gut to airways. Their functions extend beyond pathogen killing to include immune cell recruitment, tight junction maintenance, microbiome regulation, and wound healing promotion. Genetic variation in beta-defensin gene copy number, age-related declines in expression, and disease-associated dysregulation all point to these peptides as central players in epithelial health and disease.